Variability of Fluconazole Concentration in Critically Ill Patients
Completed
- Conditions
- Invasive Candidiasis
- Registration Number
- NCT02491151
- Lead Sponsor
- University Medical Center Groningen
- Brief Summary
Fluconazole is the first-line agent in the treatment of invasive candidiasis. Studies showed inappropriate drug exposure causes high mortality in critically ill patients. Under-dosing and ineffective fluconazole trough serum concentrations were found in a recent retrospective study. Variability in fluconazole exposure can be easily measured with therapeutic drug monitoring. For patient groups who are at risk for drug underexposure, therapeutic drug monitoring can be valuable regards decreasing mortality.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Patient is 18 years or older.
- Treatment with fluconazole.
- Written informed consent obtained from patient.
- Written informed consent obtained from representative of patient.
Exclusion Criteria
- Blood sampling not possible
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentrations of fluconazole in critically ill patients Up to one month Plasma concentrations of fluconazole will be determined using a validated method involving LC-MS/MS
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Medical Center Groningen
🇳🇱Groningen, Netherlands